The Master of Science in Clinical Investigation (MSCI) now accepts applications for the 2024-2026 cohort. The program’s priority deadline for merit-based scholarships is Wednesday, Feb. 28. The MSCI program is entirely online and provides clinical and translational research education.
Since the program’s inception in 2000, MSCI scholars have published over 9,500 research articles, including NEJM, JAMA, and Lancet publications. Vanderbilt’s MSCI alums and students have received a total of $24.3M+ as principal investigators of individual K and K-equivalent awards, $135.4M+ as principal investigators of R and R-equivalent awards, $1.4M+ as PI of Bridge (K99/R00) awards, and more than $109.7M in foundation grants. Of the K-awardees, 71.4% were able to convert to an R-award.
Almost 70% of MSCI alums pursue careers in academic medicine, with nearly 30% maintaining a career in industry/pharmaceuticals. Furthermore, the MSCI program at Vanderbilt has maintained a 99% completion rate.
For more information on the MSCI program, please visit https://medschool.vanderbilt.edu/msci/. If you’re interested in applying, you can do so at https://medschool.vanderbilt.edu/msci/application/.